Advertisement covers The 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012)

Medical News

Delay Antiretroviral Therapy in HIV Patients With Cryptococcal Meningitis, Researchers Recommend

November 5, 2012

Dr. David Boulware, professor of infectious diseases and international medicine at the University of Minnesota in Minneapolis, advised that in treatment-naive HIV patients with cryptococcal meningitis, the meningitis should be treated until the patients' cerebrospinal fluid (CSF) is cleared of the infection before antiretroviral therapy (ART) is administered. Boulware was speaking at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy. He made these recommendations based on a study that examined ART and delayed ART in ART-naive HIV patients with cryptococcal meningitis in Uganda and South Africa.

The researchers studied 87 patients who were randomly assigned to an efavirenz and nucleoside reverse transcriptase inhibitor ART regimen 7-11 days after starting therapy for cryptococcal meningitis, with 0.7-1.0 mg/kg per day of amphotericin and 800 mg/day of fluconazole. Another 87 patients received an ART regimen 5 weeks or more after the start of treatment for cryptococcal meningitis, when amphotericin was discontinued and fluconazole was reduced to a lower dose.

The trial was stopped in April 2012, as researchers realized that early-ART patients were 1.7 times more likely than delayed-ART patients to die within six months. Six-month mortality was 42.5 percent (37 patients) in early ART and 27.6 percent (24 patients) in delayed ART. Although the mortality differences were driven by patients who entered the trial with altered mental status, and those who did not have strong CSF inflammatory responses, Boulware stated those who were not sick showed "no benefits and no trends of benefits" from early ART.

Boulware suggested starting ART around 3 to 4 weeks when the CSF is sterile. He also emphasized the importance of making sure the CSF culture is sterile before reducing the fluconazole. He recommended a longer wait for patients with little CSF inflammation, as well as those with altered mental status.

The trial was sponsored by the National Institute of Allergy and Infectious Diseases.

Back to other news for November 2012

Adapted from:
Family Practice News
11.01.2012; M. Alexander Otto

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.


Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.